Search

CYC116

In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematological cancers. … Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition

VXA-CoV2-1

VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses a SARS-CoV-2 antigen and dsRNA adjuvant[L30493]. … This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell

9CUAB30

9 Cuab30 has been used in trials studying the treatment and prevention of HER2/Neu Positive, HER2/Neu Negative, No Evidence of Disease, Estrogen Receptor Negative, and estrogen receptor positive, among

Pristinamycin

Fradafiban

SB-743921

NVS antibody

This drug has been developed using Medarex's UltiMAb Human Antibody Development System to treat autoimmune diseases.

Tosufloxacin

Pirisudanol

Amenamevir

Amenamevir has been used in trials studying the treatment of Herpes Zoster, Herpes Simplex, Herpes Genitalis, and Safety of Amenamevir.